Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 3038514, 7 pages
https://doi.org/10.1155/2017/3038514
Research Article

Anti-OSM Antibody Inhibits Tubulointerstitial Lesion in a Murine Model of Lupus Nephritis

1Department of Pathology, Key Laboratory of Kidney Diseases of Hebei Province, Hebei Medical University, Shijiazhuang, Hebei 050017, China
2Department of Ophthalmology, People’s Hospital of Hebei Province, Shijiazhuang, Hebei 050000, China

Correspondence should be addressed to Shuxia Liu; moc.liamtoh@1002uilnasus

Received 21 December 2016; Revised 21 February 2017; Accepted 23 February 2017; Published 24 May 2017

Academic Editor: Oreste Gualillo

Copyright © 2017 Qingjuan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. V. Seshan and J. C. Jennette, “Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 2, pp. 233–248, 2009. View at Publisher · View at Google Scholar
  2. D. P. D’Cruz, M. A. Khamashta, and G. R. Hughes, “Systemic lupus erythematosus,” Lancet, vol. 369, no. 9561, pp. 587–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Hayakawa, K. Nakabayashi, M. Karube et al., “Tubulointerstitial immune complex nephritis in a patient with systemic lupus erythematosus: role of peritubular capillaritis with immune complex deposits in the pathogenesis of the tubulointerstitial nephritis,” Clinical and Experimental Nephrology, vol. 10, no. 2, pp. 146–151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Yu, L. H. Wu, Y. Tan et al., “Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system,” Kidney International, vol. 77, no. 9, pp. 820–829, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Tanaka and A. Miyajima, “Oncostatin M, a multifunctional cytokine,” Reviews of Physiology, Biochemistry and Pharmacology, vol. 149, pp. 39–52, 2003. View at Publisher · View at Google Scholar
  6. E. Robak, A. Sysa-Jedrzejowska, H. Stepien, and T. Robak, “Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus,” European Cytokine Network, vol. 8, no. 3, pp. 281–286, 1997. View at Google Scholar
  7. J. Nightingale, S. Patel, N. Suzuki et al., “Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation,” Journal of the American Society of Nephrology:JASN, vol. 15, no. 1, pp. 21–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Pollack, R. Sarkozi, Z. Banki et al., “Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling,” American Journal of Physiology. Renal Physiology, vol. 293, no. 5, pp. F1714–F1726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. W. M. Elbjeirami, L. D. Truong, A. Tawil et al., “Early differential expression of oncostatin M in obstructive nephropathy,” Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research., vol. 30, no. 7, pp. 513–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Sarkozi, K. Flucher, V. M. Haller, M. Pirklbauer, G. Mayer, and H. Schramek, “Oncostatin M inhibits TGF-beta1-induced CTGF expression via STAT3 in human proximal tubular cells,” Biochemical and Biophysical Research Communications, vol. 424, no. 4, pp. 801–806, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Sarkozi, C. Hauser, S. J. Noppert et al., “Oncostatin M is a novel inhibitor of TGF-beta1-induced matricellular protein expression,” American Journal of Physiology. Renal Physiology, vol. 301, no. 5, pp. F1014–F1025, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Liu, L. Xing, L. Wang et al., “Therapeutic effects of suppressors of cytokine signaling in diabetic nephropathy,” The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society, vol. 62, no. 2, pp. 119–128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Q. Liu, S. Liu, Y. Shi et al., “Suppressors of cytokine signaling inhibit tubular epithelial cell-myofibroblast transdifferentiation,” American Journal of Nephrology, vol. 34, no. 2, pp. 142–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Avalle, S. Pensa, G. Regis, F. Novelli, and V. Poli, “STAT1 and STAT3 in tumorigenesis: A matter of balance,” Jak-Stat, vol. 1, no. 2, pp. 65–72, 2012. View at Publisher · View at Google Scholar
  15. M. S. Kim, W. S. Lee, J. Jeong, S. J. Kim, and W. Jin, “Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer,” Oncotarget, vol. 6, no. 37, pp. 40158–40171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. D. E. Levy and J. E. Darnell Jr., “Stats: transcriptional control and biological impact,” Nature Reviews Molecular Cell Biology, vol. 3, no. 9, pp. 651–662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Bromberg and J. E. Darnell Jr., “The role of STATs in transcriptional control and their impact on cellular function,” Oncogene, vol. 19, no. 21, pp. 2468–2473, 2000. View at Publisher · View at Google Scholar
  18. P. Kachroo, M. H. Lee, L. Zhang et al., “IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer,” Journal of Experimental and Clinical Cancer Research: CR, vol. 32, no. 1, p. 97, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. H. Lee, P. Kachroo, P. C. Pagano et al., “Combination treatment with apricoxib and IL-27 enhances inhibition of epithelial-mesenchymal transition in human lung cancer cells through a STAT1 dominant pathway,” Journal of Cancer Science and Therapy, vol. 6, no. 11, pp. 468–477, 2014. View at Publisher · View at Google Scholar
  20. C. M. Pan, M. L. Wang, S. H. Chiou, H. Y. Chen, and C. W. Wu, “Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings,” Oncotarget, vol. 7, no. 37, pp. 60395–60406, 2016. View at Publisher · View at Google Scholar · View at Scopus